SIGN UP
LOG IN
News
PLUR
5.07
-1.84%
-0.10
PLURI INC: ON APRIL 15, GOT LETTER FROM NASDAQ THAT CO HAS REGAINED COMPLIANCE WITH NASDAQ LISTING RULE 5550(A)(2)
Reuters · 1d ago
Weekly Report: what happened at PLUR last week (0408-0412)?
Weekly Report · 3d ago
Pluri stock jumps 9% on US patent for immune cell production
Pluri stock jumps 9% on US patent for immune cell production. Israeli biotech company says the patent will enable mass-scale production of immune cell therapies. Pluri estimates the market will be $11.66B by 2030. The company's stock jumped 9% in morning trading.
Seeking Alpha · 04/08 14:35
Microstrategy, Apartment Income REIT, Marathon Digital among premarket gainers' pack
Microstrategy, Apartment Income REIT, Marathon Digital among premarket gainers' pack. Auddia AUUD +123% on bagging a U.S. Patent for the core AI technology it uses in its radio app. Bitcoin again surpassed the $72,000 level.
Seeking Alpha · 04/08 13:10
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Longeveron (NASDAQ:LGVN) shares moved upwards by 75.0% to $3.85 during Monday's pre-market session. PetVivo Hldgs stock increased by 17.09% and SHL Telemedicine stock moved up by 13.26%. Losers include Supernus Pharmaceuticals and G1 Therapeutics.
Benzinga · 04/08 12:09
Pluri Introduces Groundbreaking Immune Cell Expansion Technology, Secures New US Patent
Pluri Inc. Has been granted a new U.S. Patent for a novel method for expansion of immune cells using proprietary technology. The company's 3D cell expansion technology mimics the natural lymph node like environment that immune cells have in the human body. Pluri's technology represents a paradigm shift in immune cell expansion methodologies.
Benzinga · 04/08 11:07
BREAKTHROUGH IN IMMUNE CELL EXPANSION: PLURI GRANTED U.S PATENT FOR NEW METHOD
Reuters · 04/08 11:01
Weekly Report: what happened at PLUR last week (0401-0405)?
Weekly Report · 04/08 10:59
PLUR Stock Earnings: Pluri Reported Results for Q4 2023
Pluri reported results for the fourth quarter of 2023. Pluri reported earnings per share of -$1.20. The company reported revenue of $111,000. The stock is down 2.7% in the last week. Pluri is down 10% this year.
Investorplace · 04/03 18:52
Weekly Report: what happened at PLUR last week (0325-0329)?
Weekly Report · 04/01 10:56
Pluri’s Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences
Leadership from Pluri's business verticals will be presenting at the following conferences. Pluri is a leading biotechnology company that transforms cells into solutions that promote global wellbeing and sustainability. The company will be in Israel in March 2024. Pluri will present at conferences in Israel.
Barchart · 03/28 06:15
Pluri to implement a 1-for-8 reverse stock split
Pluri to implement a 1-for-8 reverse stock split on April 1. The reverse share split of the company's issued and outstanding common shares is expected to be implemented at the market open. The company added its 41.82M shares outstanding will be reduced to 5.23M shares.
Seeking Alpha · 03/27 11:09
Weekly Report: what happened at PLUR last week (0318-0322)?
Weekly Report · 03/25 10:59
Pluri’s Sustainable Cell-Based Coffee Addresses Critical Challenges Revealed in International Coffee Organization Market Report
Price instability and cost increases will impact coffee drinkers worldwide. The erratic weather conditions across the globe are creating price volatility. More than 2 billion cups of coffee are drunk each day, 400 million of them by Americans. International Coffee Organization’s 2024 Market Report addressed the price volatility challenge.
Barchart · 03/21 06:00
Engage with Pluri's Talent: Exciting Conference Appearances Ahead
Barchart · 03/19 03:00
Weekly Report: what happened at PLUR last week (0311-0315)?
Weekly Report · 03/18 10:58
Pluri Receives Patent Approval For 3D Bioreactor Technology In Plant Cell Cultivation
Benzinga · 03/11 11:11
Weekly Report: what happened at PLUR last week (0304-0308)?
Weekly Report · 03/11 10:55
Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board
Pluri Inc. Appoints attorney James Roosevelt, Jr. To the Company’s Advisory Board. The Company is a leading biotech company that transforms cells into solutions that promote global wellbeing and sustainability. James Roosevelt Jr. Will join the Company's Advisory Board in March 2024.
Barchart · 03/06 06:00
Weekly Report: what happened at PLUR last week (0226-0301)?
Weekly Report · 03/04 10:58
More
Webull provides a variety of real-time PLUR stock news. You can receive the latest news about PLURILOCK SEC INC through multiple platforms. This information may help you make smarter investment decisions.
About PLUR
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.